Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
38 lessons
14mSearchers often type "CBL-514 peptide," but Caliway's drug is a first-in-class small molecule in global Phase 3 for abdominal subcutaneous fat. Here is what trials have reported — and what is still unknown.
11mCeriello et al. followed Italian diabetes clinics for two decades and compared persistent GLP-1 users with those who stopped. The association is striking, but observational data cannot prove causation.
11mOn November 9, 2026, FDA required a class-wide warning about NAION, a rare optic nerve condition that can cause sudden vision loss. The risk is real enough to label, small in absolute terms, and still debated. Here is the evidence, drug by drug.
10mTwo antibodies that block the myostatin/activin pathway are being tested alongside GLP-1 drugs to protect lean mass. Bimagrumab's phase 2 BELIEVE trial is published in Nature Medicine. Apitegromab is FDA-approved, but only for spinal muscular atrophy. Neither is a peptide or a pill.
9mA GLP-1 program is a months-long titration that happens at the patient's kitchen table. This guide covers the operational pieces clinics need: adherence against the titration schedule, side-effect logs the prescriber reads, refill timing, check-in cadence, and the compounded-product issues FDA has flagged.
12mThe only peptides with large controlled trials for weight loss are the GLP-1 class: semaglutide, tirzepatide, and the oral options approved in 2025 and 2026. Retatrutide is next but still investigational. Here's how they work, what the trials showed, and how to access them through a licensed clinician.
9mTirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea). Here's what it is, what the trials showed, how it compares with semaglutide and retatrutide, and how to get evaluated by a licensed clinician.
10mThree incretin-era molecules, three different receptor stories. Learn how GLP-1, GIP, and glucagon pathways differ so your logs match the science labels describe.
8mRetatrutide owns PeptIQ's top blog slots. This listicle orders the beginner path: mix the vial, understand dosing, switch carefully, troubleshoot stalls, then consider stacks.
9mGLP-1s can change sleep and mood in both directions. The pattern usually comes down to dose timing, appetite changes, side effects, and the bigger metabolic picture.
11mEloralintide is Eli Lilly's once-weekly selective amylin receptor agonist. It produced up to 20.1% average weight loss at 48 weeks in Phase 2, and up to 23.3% when paired with tirzepatide. It is not approved anywhere, and its Phase 3 program will not read out before 2028.
8mCT-388 is Roche's weekly tirzepatide-class dual agonist with Phase 2 doses up to 24 mg. Here's the dosing vocabulary and the weight-loss signal searchers want.
8mAmylin + incretin is the stacking thesis behind CagriSema — and now eloralintide. Here's the clinical logic for combining pathways, without turning investigational drugs into DIY stacks.
8mMariTide is Amgen's once-monthly obesity candidate. This beginner guide covers the mechanism framing, Phase 2 headlines, and what serious trackers should log.
8mWeekly vs monthly is the real MariTide comparison. Here's how Amgen's conjugate stacks up conceptually against weekly dual/triple agonists — without fake head-to-heads.
8mGLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
8mNew head-to-head trials and real-world data from 2025-2026 reveal tirzepatide and semaglutide are not equivalent - they produce meaningfully different outcomes depending on your goals.
9mWeight regain after stopping GLP-1 treatment is common in trials. Understand the evidence, the numbers, and the questions that make a maintenance conversation useful.
7mA new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.
8mNew 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.
9mFood thoughts, hunger and weight are different outcomes. Learn what human studies show about GLP-1 treatment and what returning food noise can—and cannot—tell you.
9mYou don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
8mFinished your GLP-1 cycle and want to maintain metabolic momentum? MOTS-C is one of the most effective peptides for supporting fat oxidation and energy during GLP-1 off-cycles. Here's how to dose and time it.
9mAlready on tirzepatide and considering retatrutide? Here's exactly how to make the switch—starting doses based on your current Tirz level, what the glucagon component changes, and how to avoid common transition mistakes.
9mHitting a plateau on Retatrutide is common and usually temporary. Here's the science behind GLP-1 stalls and the practical steps to break through them.
8mAOD-9604 is a synthetic fragment of human growth hormone designed specifically to stimulate fat breakdown without the glucose or IGF-1 side effects of full HGH. Here's how it works and who it's for.
10mPhase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
11mA 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.
10mRetatrutide's triple receptor mechanism simultaneously suppresses appetite, enhances metabolic function, and activates thermogenesis. Here's the science behind why it delivers 24% body weight reduction.
10mRetatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.
9mRetatrutide is often marketed as muscle-sparing. The published scans tell a narrower story: mostly fat loss, some lean loss, and no head-to-head body-composition data against tirzepatide yet.
12mRetatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
8mNew Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.
10mRetatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.
10mRetatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.
12mGLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.
9mRetatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.
Also available at /blog for legacy links.